Interleukin-17 signaling influences CD8⁺ T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cells

References

• Amatya N, Garg AV, Gaffen SL. IL-17 signaling: the yin and the Yang. Trends Immunol. 2017 May;38(5):310–18. doi:10.1016/j.it.2017.01.006. PubMed PMID: 28254169. Pubmed Central PMCID: 5411326.
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019 Apr 16;50(4):892–906. doi:10.1016/j.immuni.2019.03.021. PubMed PMID: 30995505. Pubmed Central PMCID: PMC6474359. Epub 2019/04/18. eng.
   PubMed Web of Science ®Google Scholar
• Gorczynski RM. IL-17 signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1240:47–58. PubMed PMID: 32060887. Epub 2020/02/16. eng.
   PubMedGoogle Scholar
• Kuen DS, Kim BS, Chung Y. IL-17-Producing cells in tumor immunity: friends or foes? Immune Netw. 2020 Feb;20(1):e6. doi:10.4110/in.2020.20.e6. PubMed PMID: 32158594. Pubmed Central PMCID: PMC7049578. Epub 2020/03/12. eng.
   PubMed Web of Science ®Google Scholar
• Vitiello GA, Miller G. Targeting the interleukin-17 immune axis for cancer immunotherapy. J Exp Med. 2020;217(1):e20190456. doi: 10.1084/jem.20190456. PubMed PMID: 31727783. eng.
   PubMed Web of Science ®Google Scholar
• Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, Tocker J, Peschon J. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol. 2006 Jul 1;177(1):36–39. doi:10.4049/jimmunol.177.1.36. PubMed PMID: 16785495.
   PubMed Web of Science ®Google Scholar
• Rong Z, Wang A, Li Z, Ren Y, Cheng L, Li Y, Wang Y, Ren F, Zhang X, Hu J, et al. IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling. Cell Res. 2009 Feb;19(2):208–215. doi:10.1038/cr.2008.320. PubMed PMID: 19079364. Pubmed Central PMCID: 4603938.
   PubMed Web of Science ®Google Scholar
• Mellett M, Atzei P, Horgan A, Hams E, Floss T, Wurst W, Fallon PG, Moynagh PN. Orphan receptor IL-17RD tunes IL-17A signalling and is required for neutrophilia. Nat Commun. 2012;3(1):1119. doi:10.1038/ncomms2127. PubMed PMID: 23047677. Epub 2012/10/11. eng.
   PubMedGoogle Scholar
• Su Y, Huang J, Zhao X, Lu H, Wang W, Yang XO, Shi Y, Wang X, Lai Y, Dong C, et al. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation. Sci Immunol. 2019 Jun;7436. doi:10.1126/sciimmunol.aau9657. PubMed PMID: 31175175. Epub 2019/06/09. eng.
   Web of Science ®Google Scholar
• Goepfert A, Lehmann S, Blank J, Kolbinger F, Rondeau J-M. Structural analysis reveals that the cytokine IL-17F forms a homodimeric complex with receptor IL-17RC to drive IL-17RA-Independent signaling. Immunity. 2020;52(3):499–512.e5. doi:10.1016/j.immuni.2020.02.004.
   PubMed Web of Science ®Google Scholar
• Punt S, Langenhoff JM, Putter H, Fleuren GJ, Gorter A, Jordanova ES. The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology. 2015 Feb;4(2):e984547. doi:10.4161/2162402X.2014.984547. PubMed PMID: 25949881. Pubmed Central PMCID: PMC4404813. Epub 2015/05/08. eng.
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen X, Herjan T, Li X. The role of interleukin-17 in tumor development and progression. J Exp Med. 2019;217(1). doi:10.1084/jem.20190297.
   Web of Science ®Google Scholar
• Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med. 2011 Sep 26;208(10):2005–2016. doi:10.1084/jem.20101159. PubMed PMID: 21930765. Pubmed Central PMCID: PMC3182064. Epub 2011/09/21. eng.
   PubMed Web of Science ®Google Scholar
• Kline J, Zhang L, Battaglia L, Cohen KS, Gajewski TF. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol. 2012 Mar 15;188(6):2630–2642. doi:10.4049/jimmunol.1100845. PubMed PMID: 22312128. Pubmed Central PMCID: PMC3294164. Epub 2012/02/09. eng.
   PubMed Web of Science ®Google Scholar
• Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017 Feb;214(2):381–400. doi:10.1084/jem.20160485. PubMed PMID: 28115575. Pubmed Central PMCID: 5294847.
   PubMed Web of Science ®Google Scholar
• Pickens SR, Volin MV, AM M II, JK K, RM P, Shahrara S. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol. 2010;184(6):3233–3241. doi:10.4049/jimmunol.0903271.
   PubMed Web of Science ®Google Scholar
• Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008 May 15;14(10):3156–3167. doi:10.1158/1078-0432.CCR-07-4696. PubMed PMID: 18483384.
   PubMed Web of Science ®Google Scholar
• Iraolagoitia XL, Spallanzani RG, Torres NI, Araya RE, Ziblat A, Domaica CI, Sierra JM, Nuñez SY, Secchiari F, Gajewski TF, et al. NK cells restrain spontaneous antitumor CD8+ T cell priming through PD-1/PD-L1 interactions with dendritic cells. J Immunol. 2016 Aug 1;197(3):953–961. doi:10.4049/jimmunol.1502291. PubMed PMID: 27342842.
   PubMed Web of Science ®Google Scholar
• Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma’ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013 Apr 15;14(1):128. doi:10.1186/1471-2105-14-128. PubMed PMID: 23586463. Pubmed Central PMCID: PMC3637064. Epub 2013/04/17. eng.
   PubMedGoogle Scholar
• Núñez NG, Tosello Boari J, Ramos RN, Richer W, Cagnard N, Anderfuhren CD, Niborski LL, Bigot J, Meseure D, De La Rochere P, et al. Tumor invasion in draining lymph nodes is associated with treg accumulation in breast cancer patients. Nat Commun. 2020 06 29;11(1):3272. doi:10.1038/s41467-020-17046-2.
   PubMed Web of Science ®Google Scholar
• Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003 Apr 1;101(7):2620–2627. doi:10.1182/blood-2002-05-1461. PubMed PMID: 12411307.
   PubMed Web of Science ®Google Scholar
• Garcia-Hernandez Mde L, Hamada H, Reome JB, Misra SK, Tighe MP, Dutton RW. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol. 2010 Apr 15;184(8):4215–4227. doi:10.4049/jimmunol.0902995. PubMed PMID: 20237297. Pubmed Central PMCID: PMC2851479. Epub 2010/03/20. eng.
   PubMed Web of Science ®Google Scholar
• Martin-Orozco N, Muranski P, Chung Y, Yang X, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31(5):787–798. doi:10.1016/j.immuni.2009.09.014.
   PubMed Web of Science ®Google Scholar
• Nuñez S, Saez JJ, Fernandez D, Flores-Santibañez F, Alvarez K, Tejon G, Ruiz P, Maldonado P, Hidalgo Y, Manriquez V, et al. T helper type 17 cells contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour. Immunology. 2013 May;139(1):61–71. doi:10.1111/imm.12055. PubMed PMID: 23278668. Pubmed Central PMCID: PMC3634539. Epub 2013/01/03. eng.
   PubMed Web of Science ®Google Scholar
• Chen YS, Huang TH, Liu CL, Chen HS, Lee MH, Chen HW, Shen CR. Locally targeting the IL-17/IL-17RA axis reduced tumor growth in a murine B16F10 melanoma model. Hum Gene Ther. 2019 Mar;30(3):273–285. doi:10.1089/hum.2018.104. PubMed PMID: 30079767. Epub 2018/08/07. eng.
   PubMed Web of Science ®Google Scholar
• Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009 Jul 6;206(7):1457–1464. doi:10.1084/jem.20090207. PubMed PMID: 19564351. Pubmed Central PMCID: 2715087.
   PubMed Web of Science ®Google Scholar
• Tang Q, Li J, Zhu H, Li P, Zou Z, Xiao Y. Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators Inflamm. 2013;2013:713859–. doi:10.1155/2013/713859. PubMed PMID: 24453427. Epub 12/28. eng.
   PubMed Web of Science ®Google Scholar
• Bobek V, Kolostova K, Pinterova D, Kacprzak G, Adamiak J, Kolodziej J, Boubelik M, Kubecova M, Hoffman RM. A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma. Anticancer Res. 2010 Dec;30(12):4799–4803. PubMed PMID: 21187455. Epub 2010/12/29. eng.
   PubMed Web of Science ®Google Scholar
• Potez M, Trappetti V, Bouchet A, Fernandez-Palomo C, Güç E, Kilarski WW, Hlushchuk R, Laissue J, Djonov V. Characterization of a B16-F10 melanoma model locally implanted into the ear pinnae of C57BL/6 mice. PloS One. 2018;13(11):e0206693. doi:10.1371/journal.pone.0206693. PubMed PMID: 30395629. Pubmed Central PMCID: PMC6218054. Epub 2018/11/06. eng.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009 Jul 9;114(2):357–359. doi:10.1182/blood-2008-09-177360. PubMed PMID: 19289853. Pubmed Central PMCID: 2714210.
   PubMed Web of Science ®Google Scholar
• Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell–dependent mechanism. Blood. 2002 Mar 15;99(6):2114–2121. doi:10.1182/blood.V99.6.2114. PubMed PMID: 11877287.
   PubMed Web of Science ®Google Scholar
• Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 2005 Nov 1;175(9):6177–6189. doi:10.4049/jimmunol.175.9.6177. PubMed PMID: 16237115. Epub 2005/10/21. eng.
   PubMed Web of Science ®Google Scholar
• Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu Y-X, Schreiber H. Increasing tumor antigen expression overcomes “ignorance” to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec;17(6):737–747. doi:10.1016/S1074-7613(02)00480-6. PubMed PMID: 12479820.
   PubMed Web of Science ®Google Scholar
• He D, Li H, Yusuf N, Elmets C, Li J, Mountz J, Xu H. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010;184(5):2281–2288. doi:10.4049/jimmunol.0902574.
   PubMed Web of Science ®Google Scholar
• Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes J-M, Jiang Z, Meng YG, Peale FV, et al. An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013 Sep;19(9):1114–1123. doi:10.1038/nm.3291. PubMed PMID: 23913124.
   PubMed Web of Science ®Google Scholar
• Lu L, Pan K, Zheng HX, Li JJ, Qiu HJ, Zhao JJ, Weng D-S, Pan Q-Z, Wang D-D, Jiang S-S, et al. IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival. J Immunother (1991). 2013 Oct;36(8):451–458. doi:10.1097/CJI.0b013e3182a802cf. PubMed PMID: 23994890.
   Web of Science ®Google Scholar
• Bar E, Whitney PG, Moor K, E Sousa CR, LeibundGut-Landmann S. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity. 2014 Jan 16;40(1):117–127. doi:10.1016/j.immuni.2013.12.002. PubMed PMID: 24412614.
   PubMed Web of Science ®Google Scholar
• Fiocca Vernengo F, Beccaria CG, Araujo Furlan CL, Tosello Boari J, Almada L, Gorosito Serrán M, Gazzoni Y, Montes CL, Acosta Rodríguez EV, Gruppi A, et al.CD8 + T cell immunity is compromised by anti-CD20 treatment and rescued by interleukin-17A. mBio. 2020 May;12113. doi:10.1128/mBio.00447-20 PubMed PMID: 32398312. Epub 2020/05/14. eng.
   PubMed Web of Science ®Google Scholar
• Tosello Boari J, Araujo Furlan CL, Fiocca Vernengo F, Rodriguez C, Ramello MC, Amezcua Vesely MC, Gorosito Serrán M, Nuñez NG, Richer W, Piaggio E, et al. IL-17RA-Signaling modulates CD8+ T cell survival and exhaustion during Trypanosoma cruzi infection. Front Immunol. 2018;9:2347. doi:10.3389/fimmu.2018.02347. PubMed PMID: 30364284. Pubmed Central PMCID: 6193063.
   PubMed Web of Science ®Google Scholar
• Dawod B, Liu J, Gebremeskel S, Yan C, Sappong A, Johnston B, Hoskin DW, Marshall JS, Wang J. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas. Science Reports. 2020 Aug 07;10(1):13343. doi:10.1038/s41598-020-70231-7.
   PubMed Web of Science ®Google Scholar
• Kim B-S, Kuen D-S, Koh C-H, Kim H-D, Chang SH, Kim S, Jeon YK, Park Y-J, Choi G, Kim J, et al. Type 17 immunity promotes the exhaustion of CD8+ T cells in cancer. J Immunother Cancer. 2021;9(6):e002603. doi:10.1136/jitc-2021-002603.
   PubMed Web of Science ®Google Scholar
• Ahrends T, Spanjaard A, Pilzecker B, Bąbała N, Bovens A, Xiao Y, Jacobs H, Borst J. CD4(+) T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity. 2017 Nov 21;47(5):848–61 e5. doi:10.1016/j.immuni.2017.10.009. PubMed PMID: 29126798. Epub 2017/11/12. eng.
   PubMed Web of Science ®Google Scholar
• Ueha S, Yokochi S, Ishiwata Y, Ogiwara H, Chand K, Nakajima T, Hachiga K, Shichino S, Terashima Y, Toda E, et al. Robust antitumor effects of combined anti–CD4-Depleting antibody and anti–PD-1/PD-L1 immune checkpoint antibody treatment in mice. Cancer Immunol Res. 2015 Jun;3(6):631–640. doi:10.1158/2326-6066.CIR-14-0190. PubMed PMID: 25711759. Epub 2015/02/26. eng.
   PubMed Web of Science ®Google Scholar
• Penaloza-MacMaster P, Provine NM, Blass E, Barouch DH. CD4 T cell depletion substantially augments the rescue potential of PD-L1 blockade for deeply exhausted CD8 T cells. J Immunol. 2015;195(3):1054–1063. doi:10.4049/jimmunol.1403237.
   PubMed Web of Science ®Google Scholar
• Wang X, Sun R, Hao X, Lian Z-X, Wei H, Tian Z. IL-17 constrains natural killer cell activity by restraining IL-15–driven cell maturation via SOCS3. Proc Natl Acad Sci USA. 2019;116(35):17409–17418. doi:10.1073/pnas.1904125116.
   PubMed Web of Science ®Google Scholar
• Lu L, Weng C, Mao H, Fang X, Liu X, Wu Y, Cao X, Li B, Chen X, Gan Q, et al. IL-17A promotes migration and tumor killing capability of B cells in esophageal squamous cell carcinoma. Oncotarget. 2016 Apr 19;7(16):21853–21864. doi:10.18632/oncotarget.7869. PubMed PMID: 26942702. Pubmed Central PMCID: PMC5008328. Epub 2016/03/05. eng.
   PubMedGoogle Scholar
• Fridman WH, Petitprez F, Meylan M, Chen TW, Sun CM, Roumenina LT, Sautès-Fridman C. B cells and cancer: to B or not to B? J Exp Med. 2021 Jan 4;218(1). 10.1084/jem.20200851. PubMed PMID: 33601413. Pubmed Central PMCID: PMC7754675 Daiichi Sankyio, and Eisai outside the submitted work. No other disclosures were reported. Epub 2021/02/19. eng.
   PubMed Web of Science ®Google Scholar
• Wang J, Liu X, Ji J, Luo J, Zhao Y, Zhou X, Zheng J, Guo M, Liu Y. Orthotopic and heterotopic murine models of Pancreatic cancer exhibit different immunological microenvironments and different responses to immunotherapy. Front Immunol. 2022 July 07;13. English. doi:10.3389/fimmu.2022.863346.
   Web of Science ®Google Scholar
• Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995 Dec;3(6):811–821. doi:10.1016/1074-7613(95)90070-5. PubMed PMID: 8777726. Epub 1995/12/01. eng.
   PubMed Web of Science ®Google Scholar
• Kuestner R, Taft D, Haran A, Brandt CS, Brender T, Lum K, Harder B, Okada S, Ostrander CD, Kreindler JL, et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol. 2007;179(8):5462–5473. doi:10.4049/jimmunol.179.8.5462.
   PubMed Web of Science ®Google Scholar
• Yang RB, Ng CK, Wasserman SM, Kömüves LG, Gerritsen ME, Topper JN. A novel interleukin-17 receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling. J Biol Chem. 2003 Aug 29;278(35):33232–33238. doi:10.1074/jbc.M305022200. PubMed PMID: 12807873. Epub 2003/06/17. eng.
   PubMed Web of Science ®Google Scholar
• Monin L, Gaffen SL. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and Therapeutic Implications. Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):a028522. doi:10.1101/cshperspect.a028522. PubMed PMID: 28620097. Pubmed Central PMCID: PMC5732092. Epub 2017/06/18. eng.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011 Feb 25;34(2):149–162. doi:10.1016/j.immuni.2011.02.012. PubMed PMID: 21349428. Epub 2011/02/26. eng.
   PubMed Web of Science ®Google Scholar
• Dhamija S, Winzen R, Doerrie A, Behrens G, Kuehne N, Schauerte C, Neumann E, Dittrich-Breiholz O, Kracht M, Holtmann H, et al. Interleukin-17 (IL-17) and IL-1 activate translation of overlapping sets of mRnas, including that of the negative regulator of inflammation, MCPIP1. J Biol Chem. 2013 Jun 28;288(26):19250–19259. doi:10.1074/jbc.M113.452649. PubMed PMID: 23658019. Pubmed Central PMCID: PMC3696695. Epub 2013/05/10. eng.
   PubMed Web of Science ®Google Scholar
• Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch A-M, Wu J, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Nov 15;491(7424):399–405. doi:10.1038/nature11547. PubMed PMID: 23103869. Pubmed Central PMCID: PMC3530898. Epub 2012/10/30. eng.
   PubMed Web of Science ®Google Scholar
• Chédotal A, Kerjan G, Moreau-Fauvarque C. The brain within the tumor: new roles for axon guidance molecules in cancers. Cell Death Differ. 2005 Aug;12(8):1044–1056. doi:10.1038/sj.cdd.4401707. PubMed PMID: 16015381. Epub 2005/07/15. eng.
   PubMed Web of Science ®Google Scholar
• Dlamini Z, Mathabe K, Padayachy L, Marima R, Evangelou G, Syrigos KN, Bianchi A, Lolas G, Hull R. Many voices in a choir: tumor-induced neurogenesis and neuronal driven alternative splicing sound like suspects in tumor growth and dissemination. Cancers Basel. 2021 Apr 29;13(9):2138. doi:10.3390/cancers13092138. PubMed PMID: 33946706. Pubmed Central PMCID: PMC8125307. Epub 2021/05/06. eng.
   PubMed Web of Science ®Google Scholar
• Walker C, Mojares E, Del Rio Hernandez A. Role of extracellular matrix in development and cancer progression. Int J Mol Sci. 2018 10 04;19(10):3028. doi:10.3390/ijms19103028.
   PubMed Web of Science ®Google Scholar
• Litan A, Langhans SA. Cancer as a channelopathy: ion channels and pumps in tumor development and progression. Front Cell Neurosci. 2015 March 17;9. English. doi:10.3389/fncel.2015.00086.
   PubMed Web of Science ®Google Scholar
• Chai BY, Yip WK, Dusa N, Mohtarrudin N, Seow HF. Loss of interleukin-17RA expression is associated with tumour progression in colorectal carcinoma. Pathol Oncol Res. 2020 Oct;26(4):2291–2298. doi:10.1007/s12253-020-00820-4. PubMed PMID: 32462420. Epub 2020/05/29. eng.
   PubMed Web of Science ®Google Scholar
• Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003 Aug 1;56(3):171–182. doi:10.1002/pros.10238. PubMed PMID: 12772186. Epub 2003/05/29. eng.
   PubMed Web of Science ®Google Scholar
• Girondel C, Meloche S. Interleukin-17 receptor D in physiology, inflammation and cancer. Front Oncol. 2021;11:656004. doi:10.3389/fonc.2021.656004. PubMed PMID: 33833999. Pubmed Central PMCID: PMC8021910. Epub 2021/04/10. eng.
   PubMed Web of Science ®Google Scholar
• Yan C, Lei Y, Lin TJ, Hoskin DW, Ma A, Wang J. IL-17RC is critically required to maintain baseline A20 production to repress JNK isoform-dependent tumor-specific proliferation. Oncotarget. 2017 Jun 27;8(26):43153–43168. doi:10.18632/oncotarget.17820. PubMed PMID: 28562353. Pubmed Central PMCID: PMC5522135. Epub 2017/06/01. eng.
   PubMedGoogle Scholar
• Yan C, Huang WY, Boudreau J, Mayavannan A, Cheng Z, Wang J. IL-17R deletion predicts high-grade colorectal cancer and poor clinical outcomes. Int J Cancer. 2019 Jul 15;145(2):548–558. doi:10.1002/ijc.32122. PubMed PMID: 30628053. Epub 2019/01/11. eng.
   PubMed Web of Science ®Google Scholar
• Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, et al. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer. 2023 07 31;4(9):1292–1308. doi:10.1038/s43018-023-00610-2.
   PubMedGoogle Scholar